NASDAQ:BIOT

Biotech Acquisition (BIOT) Stock Price, News & Analysis

→ Could Bitcoin Literally FORCE This Crypto To Rocket Up? (From Paradigm Press) (Ad)

Free BIOT Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $10.14
▼
$10.19
50-Day Range: $10.08
▼
$10.32
52-Week Range: $8.30
▼
$10.41

Volume: 44,400 shs
Average Volume: 244,605 shs
Market Capitalization: $291.81 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Biotech Acquisition alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Biotech Acquisition Stock (NASDAQ:BIOT)

Biotech Acquisition Company does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

BIOT Stock News Headlines

April 17, 2024 | finance.yahoo.com

Essential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral Capsules

April 16, 2024 | finance.yahoo.com

PharmAlliance Announces Acquisition of CHEORS

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 15, 2024 | finance.yahoo.com

Global Directory Unveils Top 1,000 Pharmaceutical and Biotechnology Companies for 2024

April 12, 2024 | bizjournals.com

Eliem pursues acquisition of New Jersey biotech after halting programs

April 11, 2024 | finance.yahoo.com

Vertex Pharmaceuticals Incorporated: Vertex: $4.9 Billion Acquisition of Alpine Immune Sciences Expands Kidney-Disease Portfolio

April 10, 2024 | marketwatch.com

Vera Therapeutics Shares Rise 9.9% After Alpine Acquisition

April 10, 2024 | bizjournals.com

Vertex to acquire Seattle biotech for $4.9B

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 10, 2024 | msn.com

Vertex buying Seattle biotech for $4.9 billion, its biggest acquisition ever

April 8, 2024 | bizjournals.com

Biotech layoffs tracker: 14 biotechs cut over 300 jobs in Q1 2024

April 6, 2024 | finance.yahoo.com

2 Biotech Stocks to Buy Hand Over Fist in April

April 5, 2024 | finance.yahoo.com

Johnson & Johnson: J&J: Shockwave Acquisition Adds Fast-Growing Medical Devices

April 4, 2024 | msn.com

Bristol Myers Squibb to lay off hundreds of workers following its $4.8B merger with this San Diego biotech

April 4, 2024 | markets.businessinsider.com

Mitsui & Co., ROHTO Pharmaceutical To Acquire Shares In Eu Yan Sang International

April 4, 2024 | marketwatch.com

Rohto Pharmaceutical, Mitsui & Co. to Acquire Singapore-Based Eu Yan Sang -- Update

April 3, 2024 | msn.com

Genmab Strengthens Oncology Portfolio With $1.8 Billion Acquisition of ProfoundBio

April 2, 2024 | bizjournals.com

Merz offers $185 million for assets of bankrupt biotech

April 2, 2024 | finance.yahoo.com

Apotex to Acquire Searchlight Pharma, a Canadian Specialty Branded Pharmaceutical Leader

April 2, 2024 | bizjournals.com

March M&A roundup: Biotech, buyers, and digital health

April 1, 2024 | finance.yahoo.com

Vallen Distribution Completes Acquisition of Wesco Integrated Supply

March 31, 2024 | seekingalpha.com

Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate

March 27, 2024 | marketwatch.com

Biotech Group Acquisition Withdraws IPO

March 26, 2024 | wsj.com

M&A Gathers Steam for Biotech Startups

March 21, 2024 | fool.com.au

Why this exciting ASX biotech stock could be a future star

March 21, 2024 | bizjournals.com

Zoning barriers and limited space: How biotech can expand on L.A.'s Westside

March 19, 2024 | bizjournals.com

PureTech made millions on Karuna acquisition. Here’s what it plans to return to shareholders.

See More Headlines

Receive BIOT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biotech Acquisition and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/18/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:BIOT
CUSIP: N/A
CIK: 1825413
Web: bioacq.com
Phone: 212-227-1905
Fax: N/A
Employees: 4
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-6,860,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -42.22%
Return on Assets: 3.48%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.03
Quick Ratio: 0.03

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.95) per share
Price / Book: -10.68

Miscellaneous

Outstanding Shares: 28,750,000
Free Float: 23,288,000
Market Cap: $291.81 million
Optionable: Not Optionable
Beta: -0.12

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Michael Shleifer Ph.D. (Age 48)
Chairman & CEO
Mr. Thomas Fratacci (Age 44)
CFO & Treasurer
Mr. Ivan Jarry (Age 44)
Chief Operating Officer
Mr. Albert F. Hummel M.B.A. (Age 76)
Chief Investment Officer & Director

Key Competitors

View All Competitors

This page (NASDAQ:BIOT) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Biotech Acquisition (BIOT) Stock Price, News & Analysis

About Biotech Acquisition Stock (NASDAQ:BIOT)

BIOT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info